This is an abbreviated version! For detailed information about beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase, go to the full flat file.
(GnT)-III, acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-glycopeptide beta4-, III, beta(1,4)-N-acetylglucosaminyltransferase III, beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, beta-1,4-N-acetylglucosaminyltransferase III, beta-D-mannoside beta-1,4-N-acetylglucosaminyltransferase, beta1,4-N-acetylglucosaminyltransferase III, EC 2.4.1.51, GlcNAc-transferase-III, GlcNAcTase-III, GnT-III, GnTIII, Golgi beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase III, MGAT3, N-acetyl-glucosaminyltransferase III, N-acetylglucosaminyltransferase III, N-acetylglucosaminyltransferase-III, N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase III, uridine diphosphate (UDP)-N-acetylglucosamin/beta-D-mannoside beta-1,4-N-acetylglucosaminyltransferase III, uridine diphosphoacetylglucosamine-glycopeptide beta4-acetylglucosaminyltransferase III
GnT-III expression significantly increases ovarian cancer growth and metastasis and increases the expansion of the ovarian cancer stem cell (CSC) population
enzyme GnT-III is strongly expressed in cytotrophoblast (CTBs), syncytiotrophoblast (STBs), and the trophoblast columns (TCs) of human placental villi, and decidual cells in maternal decidua. The expression of GnT-III is decreased in preeclampsia placentas compared with the normal control placentas
human first trimester villous tissues from normal pregnancies and third trimester placentas from pregnancies with or without preeclampsia (PE) are used for the detection of GnTIII expression
human first trimester villous tissues from normal pregnancies and third trimester placentas from pregnancies with or without preeclampsia (PE) are used for the detection of GnTIII expression